Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity

• DOI: 10.1007/s12672-024-01011-2
• Publication Date: 2024-05-16T11:02:10Z
• Authors: Yulian Xu; Xueli Sun; Yunguang Tong
• Keywords: 0301 basic medicine; 03 medical and health sciences; IL-12; Anti-tumor immunity; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Review; Combination therapy; Cytokine; RC254-282

AbstractInterleukin-12 (IL-12) can be used as an immunomodulator in cancer immunotherapy. And it has demonstrated enormous potential in inhibiting tumor growth and improving the tumor microenvironment (TME) by several preclinical models. However, some disappointing results have showed in the early clinical trials when IL-12 used as a single agent for systemic cancer therapy. Combination therapy is an effective way to significantly fulfill the great potential of IL-12 as an immunomodulator. Here, we discuss the effects of IL-12 combined with traditional methods (chemotherapy, radiotherapy and surgery), targeted therapy or immunotherapy in the preclinical and clinical studies. Moreover, we summarized the potential mechanism underlying the anti-tumor effect of IL-12 in the combination strategies. And we also discussed the delivery methods and tumor-targeted modification of IL-12 and outlines future prospects for IL-12 as an immunomodulator.